Jingjing Ben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingjing Ben has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Qi Chen
Department of Pathophysiology, Key Laboratory of Targeted Intervention of Cardiovascular Disease and Molecular Intervention (X.B., Y.W., W.Z., Y.Y., Y.D., J.L., H.B., Q.Y., B.J., J.B., H.Z., X.L., Xudong Zhu, Qi Chen), Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, China
10 shared publications Hui Bai
Key Laboratory of Targeted Intervention of Cardiovascular Disease and Molecular Intervention of Jiangsu Province, Nanjing, Jiangsu, China (C.W., H.H., L.C., M.Z., Y.Y., S.L., H.S., C.L., H.B., J.B., X.Z., X.L., Q.Y., D.W., H.Z., Q.C.).
9 shared publicationsXudong Zhu
Key Laboratory of Targeted Intervention of Cardiovascular Disease and Molecular Intervention of Jiangsu Province, Nanjing, Jiangsu, China (C.W., H.H., L.C., M.Z., Y.Y., S.L., H.S., C.L., H.B., J.B., X.Z., X.L., Q.Y., D.W., H.Z., Q.C.).
9 shared publicationsQing Yang
Key Laboratory of Targeted Intervention of Cardiovascular Disease and Molecular Intervention of Jiangsu Province, Nanjing, Jiangsu, China (C.W., H.H., L.C., M.Z., Y.Y., S.L., H.S., C.L., H.B., J.B., X.Z., X.L., Q.Y., D.W., H.Z., Q.C.).
8 shared publicationsXiaoyu Li
Key Laboratory of Targeted Intervention of Cardiovascular Disease and Molecular Intervention of Jiangsu Province, Nanjing, Jiangsu, China (C.W., H.H., L.C., M.Z., Y.Y., S.L., H.S., C.L., H.B., J.B., X.Z., X.L., Q.Y., D.W., H.Z., Q.C.).
8 shared publications- Hanwen Zhang
School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
6 shared publications
Latest Publications
- 10 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (19) , 1904-1924
CCND1 Mitigates Ischemia-Induced Pathological Cardiac Remodeling by Promoting Cardiac Monocyte–Derived Macrophage Transition to a Reparative Phenotype
BACKGROUND: The innate immune system plays a pivotal role in orchestrating the response to myocardial infarction (MI), with monocytes and macrophages acting as central mediators of tissue injury and repair. Following MI, a dynamic sequence of inflammatory, anti-inflammatory, and reparative phases unfolds over the course of several days. While timely resolution of inflammation and initiation of reparative programs are critical for favorable cardiac remodeling and improved long-term outcomes, the mechanisms by which recruited monocyte-derived macrophages are instructed within the postinfarct niche to adopt a reparative phenotype remain incompletely understood. METHODS: Human peripheral blood mononuclear cells were isolated from individuals with and without MI for single-cell RNA sequencing analysis. The murine cardiac monocyte-derived macrophage behaviors after MI were characterized by genetic lineage tracing, lineage tracing plus bone marrow transplantation, metabolite profiling, and cell phenotyping approaches. The role of macrophage CCND1 (cyclin D1) in MI-induced adverse remodeling was investigated using macrophage-specific Ccnd1 knockout mice. Epigenetic experiments were conducted to study the mechanisms underlying metabolic reprogramming and macrophage phenotypic transition. The therapeutic efficacy of lentivirus-targeting macrophage CCND1 and its downstream regulator PDK4 (pyruvate dehydrogenase kinase 4) were assessed in vivo using an MI mouse model. RESULTS: We found that CCND1 levels in peripheral blood mononuclear cells, monocytes, and cardiac macrophages from patients with MI were significantly decreased. Both macrophage-specific and monocyte-derived macrophage–specific deletion of CCND1 worsened MI-induced cardiac dysfunction and adverse remodeling, driven by amplified inflammatory responses. Mechanistically, CCND1 directly interacted with PDK4 and facilitated its ubiquitination by recruiting RPL11 (ribosomal protein L11) and mouse double minute 2. Through this axis, CCND1 suppressed PDK4-driven PDH (pyruvate dehydrogenase) phosphorylation, enhanced glucose oxidation, and shifted macrophages toward an anti-inflammatory phenotype. Targeted overexpression of the CCND1-PDK4 binding motif or knockdown of PDK4 in macrophages improved cardiac function and mitigated adverse remodeling after MI, independent of the canonical cell cycle–regulatory role of CCND1. CONCLUSIONS: Our findings identify the CCND1-PDK4 axis as a key regulator of macrophage functional reprogramming toward a reparative phenotype after MI, highlighting it as a potential therapeutic target in postinfarction remodeling.
- 10 November 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (19) , 1904-1924
CCND1 Mitigates Ischemia-Induced Pathological Cardiac Remodeling by Promoting Cardiac Monocyte–Derived Macrophage Transition to a Reparative Phenotype
BACKGROUND: The innate immune system plays a pivotal role in orchestrating the response to myocardial infarction (MI), with monocytes and macrophages acting as central mediators of tissue injury and repair. Following MI, a dynamic sequence of inflammatory, anti-inflammatory, and reparative phases unfolds over the course of several days. While timely resolution of inflammation and initiation of reparative programs are critical for favorable cardiac remodeling and improved long-term outcomes, the mechanisms by which recruited monocyte-derived macrophages are instructed within the postinfarct niche to adopt a reparative phenotype remain incompletely understood. METHODS: Human peripheral blood mononuclear cells were isolated from individuals with and without MI for single-cell RNA sequencing analysis. The murine cardiac monocyte-derived macrophage behaviors after MI were characterized by genetic lineage tracing, lineage tracing plus bone marrow transplantation, metabolite profiling, and cell phenotyping approaches. The role of macrophage CCND1 (cyclin D1) in MI-induced adverse remodeling was investigated using macrophage-specific Ccnd1 knockout mice. Epigenetic experiments were conducted to study the mechanisms underlying metabolic reprogramming and macrophage phenotypic transition. The therapeutic efficacy of lentivirus-targeting macrophage CCND1 and its downstream regulator PDK4 (pyruvate dehydrogenase kinase 4) were assessed in vivo using an MI mouse model. RESULTS: We found that CCND1 levels in peripheral blood mononuclear cells, monocytes, and cardiac macrophages from patients with MI were significantly decreased. Both macrophage-specific and monocyte-derived macrophage–specific deletion of CCND1 worsened MI-induced cardiac dysfunction and adverse remodeling, driven by amplified inflammatory responses. Mechanistically, CCND1 directly interacted with PDK4 and facilitated its ubiquitination by recruiting RPL11 (ribosomal protein L11) and mouse double minute 2. Through this axis, CCND1 suppressed PDK4-driven PDH (pyruvate dehydrogenase) phosphorylation, enhanced glucose oxidation, and shifted macrophages toward an anti-inflammatory phenotype. Targeted overexpression of the CCND1-PDK4 binding motif or knockdown of PDK4 in macrophages improved cardiac function and mitigated adverse remodeling after MI, independent of the canonical cell cycle–regulatory role of CCND1. CONCLUSIONS: Our findings identify the CCND1-PDK4 axis as a key regulator of macrophage functional reprogramming toward a reparative phenotype after MI, highlighting it as a potential therapeutic target in postinfarction remodeling.
- 19 June 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (3)
Glycine Receptor α2 Mediates Vasodilation via Endothelial eNOS Signaling
BACKGROUND: Endothelium-derived NO is an important vasodilator essential for maintaining vascular homeostasis. However, how eNOS (endothelial nitric oxide synthase) is regulated in hypertension conditions is not yet fully understood. In this study, we describe a critical role of the GLRA2 (α2 subunit of glycine receptor) in modulating eNOS signaling and blood pressure regulation. METHODS: Endothelial-specific Glra2 -deficient mice and the adeno-associated viral-transfected mice were generated to assess the role of GLRA2 in hypertension models. Endothelium-dependent relaxation response and whole-cell patch clamp recording were determined. RESULTS: We first demonstrated selective expression of GLRA2 in arterial endothelial cells. Activation of GLRA2 by its ligand, glycine, effectively counteracts hypertension in a GLRA2-dependent manner. Our patient study indicated a negative correlation between plasma levels of glycine and blood pressure. Furthermore, we showed that endothelial GLRA2 regulates vasodilation by promoting NO production, rather than functioning solely as a chloride channel. Mechanistically, GLRA2 facilitates the phosphorylation of glycogen synthase kinase-3β at Ser9, which activates the AKT/eNOS signaling pathway in the endothelium, leading to increased NO release. CONCLUSIONS: This study discovers that a novel endothelial GLRA2 pathway holds significant potential for developing new strategies to control hypertension.
- 19 June 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (3)
Glycine Receptor α2 Mediates Vasodilation via Endothelial eNOS Signaling
BACKGROUND: Endothelium-derived NO is an important vasodilator essential for maintaining vascular homeostasis. However, how eNOS (endothelial nitric oxide synthase) is regulated in hypertension conditions is not yet fully understood. In this study, we describe a critical role of the GLRA2 (α2 subunit of glycine receptor) in modulating eNOS signaling and blood pressure regulation. METHODS: Endothelial-specific Glra2 -deficient mice and the adeno-associated viral-transfected mice were generated to assess the role of GLRA2 in hypertension models. Endothelium-dependent relaxation response and whole-cell patch clamp recording were determined. RESULTS: We first demonstrated selective expression of GLRA2 in arterial endothelial cells. Activation of GLRA2 by its ligand, glycine, effectively counteracts hypertension in a GLRA2-dependent manner. Our patient study indicated a negative correlation between plasma levels of glycine and blood pressure. Furthermore, we showed that endothelial GLRA2 regulates vasodilation by promoting NO production, rather than functioning solely as a chloride channel. Mechanistically, GLRA2 facilitates the phosphorylation of glycogen synthase kinase-3β at Ser9, which activates the AKT/eNOS signaling pathway in the endothelium, leading to increased NO release. CONCLUSIONS: This study discovers that a novel endothelial GLRA2 pathway holds significant potential for developing new strategies to control hypertension.
- Open Access
- 10 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Endothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy
Many important vascular diseases including neointimal hyperplasia and atherosclerosis are characterized by the endothelial cell (EC) injury-initiated pathological vascular remodeling. However, the endogenous regulatory mechanisms underlying it are not fully understood. The present study investigates regulatory role of major vault protein (MVP) in the pathogenesis of vascular remodeling via controlling EC injury. By generating male murine vascular disease models, we find that ablation of endothelial MVP increases neointima formation and promotes atherosclerosis. Mechanistically, MVP directly binds with Parkin and inhibits the ubiquitination and proteasomal degradation of Parkin by dissociating the E3 ligase NEDD4L from Parkin, leading to activation of Parkin-mediated mitophagy pathway in the EC. Genetic modulation of endothelial MVP and Parkin influences the mitophagy, apoptosis, and neointima formation. These results demonstrate that MVP acts as an intracellular regulator promoting Parkin-mediated mitophagy. Our findings suggest that MVP/NEDD4L/Parkin axis may serve as the therapeutic target for treating intimal hyperplasia and atherosclerosis.
- 10 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessEndothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy
Many important vascular diseases including neointimal hyperplasia and atherosclerosis are characterized by the endothelial cell (EC) injury-initiated pathological vascular remodeling. However, the endogenous regulatory mechanisms underlying it are not fully understood. The present study investigates regulatory role of major vault protein (MVP) in the pathogenesis of vascular remodeling via controlling EC injury. By generating male murine vascular disease models, we find that ablation of endothelial MVP increases neointima formation and promotes atherosclerosis. Mechanistically, MVP directly binds with Parkin and inhibits the ubiquitination and proteasomal degradation of Parkin by dissociating the E3 ligase NEDD4L from Parkin, leading to activation of Parkin-mediated mitophagy pathway in the EC. Genetic modulation of endothelial MVP and Parkin influences the mitophagy, apoptosis, and neointima formation. These results demonstrate that MVP acts as an intracellular regulator promoting Parkin-mediated mitophagy. Our findings suggest that MVP/NEDD4L/Parkin axis may serve as the therapeutic target for treating intimal hyperplasia and atherosclerosis.
- 17 April 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 81, 101246
MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance
- 17 April 2025
- Published by Elsevier in Drug Resistance Updates
- Vol. 81, 101246
MVP-LCN2 axis triggers evasion of ferroptosis to drive hepatocarcinogenesis and sorafenib resistance
- 16 August 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (5) , 596-613
Lysozyme 1 Inflamed CCR2 + Macrophages Promote Obesity-Induced Cardiac Dysfunction
BACKGROUND: Macrophages are key players in obesity-associated cardiovascular diseases, which are marked by inflammatory and immune alterations. However, the pathophysiological mechanisms underlying macrophage’s role in obesity-induced cardiac inflammation are incompletely understood. Our study aimed to identify the key macrophage population involved in obesity-induced cardiac dysfunction and investigate the molecular mechanism that contributes to the inflammatory response. METHODS: In this study, we used single-cell RNA-sequencing analysis of Cd45 + CD11b + F4/80 + cardiac macrophages to explore the heterogeneity of cardiac macrophages. The CCR2 + (C-C chemokine receptor 2) macrophages were specifically removed by a dual recombinase approach, and the macrophage CCR2 was deleted to investigate their functions. We also performed cleavage under target and tagmentation analysis, chromatin immunoprecipitation-polymerase chain reaction, luciferase assay, and macrophage-specific lentivirus transfection to define the impact of lysozyme C in macrophages on obesity-induced inflammation. RESULTS: We find that the Ccr2 cluster undergoes a functional transition from homeostatic maintenance to proinflammation. Our data highlight specific changes in macrophage behavior during cardiac dysfunction under metabolic challenge. Consistently, inducible ablation of CCR2 + CX3CR1 + macrophages or selective deletion of macrophage CCR2 prevents obesity-induced cardiac dysfunction. At the mechanistic level, we demonstrate that the obesity-induced functional shift of CCR2-expressing macrophages is mediated by the CCR2/activating transcription factor 3/lysozyme 1/NF-κB (nuclear factor kappa B) signaling. Finally, we uncover a noncanonical role for lysozyme 1 as a transcription activator, binding to the RelA promoter, driving NF-κB signaling, and strongly promoting inflammation and cardiac dysfunction in obesity. CONCLUSIONS: Our findings suggest that lysozyme 1 may represent a potential target for the diagnosis of obesity-induced inflammation and the treatment of obesity-induced heart disease.
- 16 August 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (5) , 596-613
Lysozyme 1 Inflamed CCR2 + Macrophages Promote Obesity-Induced Cardiac Dysfunction
BACKGROUND: Macrophages are key players in obesity-associated cardiovascular diseases, which are marked by inflammatory and immune alterations. However, the pathophysiological mechanisms underlying macrophage’s role in obesity-induced cardiac inflammation are incompletely understood. Our study aimed to identify the key macrophage population involved in obesity-induced cardiac dysfunction and investigate the molecular mechanism that contributes to the inflammatory response. METHODS: In this study, we used single-cell RNA-sequencing analysis of Cd45 + CD11b + F4/80 + cardiac macrophages to explore the heterogeneity of cardiac macrophages. The CCR2 + (C-C chemokine receptor 2) macrophages were specifically removed by a dual recombinase approach, and the macrophage CCR2 was deleted to investigate their functions. We also performed cleavage under target and tagmentation analysis, chromatin immunoprecipitation-polymerase chain reaction, luciferase assay, and macrophage-specific lentivirus transfection to define the impact of lysozyme C in macrophages on obesity-induced inflammation. RESULTS: We find that the Ccr2 cluster undergoes a functional transition from homeostatic maintenance to proinflammation. Our data highlight specific changes in macrophage behavior during cardiac dysfunction under metabolic challenge. Consistently, inducible ablation of CCR2 + CX3CR1 + macrophages or selective deletion of macrophage CCR2 prevents obesity-induced cardiac dysfunction. At the mechanistic level, we demonstrate that the obesity-induced functional shift of CCR2-expressing macrophages is mediated by the CCR2/activating transcription factor 3/lysozyme 1/NF-κB (nuclear factor kappa B) signaling. Finally, we uncover a noncanonical role for lysozyme 1 as a transcription activator, binding to the RelA promoter, driving NF-κB signaling, and strongly promoting inflammation and cardiac dysfunction in obesity. CONCLUSIONS: Our findings suggest that lysozyme 1 may represent a potential target for the diagnosis of obesity-induced inflammation and the treatment of obesity-induced heart disease.
- Open Access
- 21 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Disruption of TIGAR-TAK1 alleviates immunopathology in a murine model of sepsis
Macrophage-orchestrated inflammation contributes to multiple diseases including sepsis. However, the underlying mechanisms remain to be defined clearly. Here, we show that macrophage TP53-induced glycolysis and apoptosis regulator (TIGAR) is up-regulated in murine sepsis models. When myeloid Tigar is ablated, sepsis induced by either lipopolysaccharide treatment or cecal ligation puncture in male mice is attenuated via inflammation inhibition. Mechanistic characterizations indicate that TIGAR directly binds to transforming growth factor β-activated kinase (TAK1) and promotes tumor necrosis factor receptor-associated factor 6-mediated ubiquitination and auto-phosphorylation of TAK1, in which residues 152-161 of TIGAR constitute crucial motif independent of its phosphatase activity. Interference with the binding of TIGAR to TAK1 by 5Z-7-oxozeaenol exhibits therapeutic effects in male murine model of sepsis. These findings demonstrate a non-canonical function of macrophage TIGAR in promoting inflammation, and confer a potential therapeutic target for sepsis by disruption of TIGAR-TAK1 interaction.
- 21 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessDisruption of TIGAR-TAK1 alleviates immunopathology in a murine model of sepsis
Macrophage-orchestrated inflammation contributes to multiple diseases including sepsis. However, the underlying mechanisms remain to be defined clearly. Here, we show that macrophage TP53-induced glycolysis and apoptosis regulator (TIGAR) is up-regulated in murine sepsis models. When myeloid Tigar is ablated, sepsis induced by either lipopolysaccharide treatment or cecal ligation puncture in male mice is attenuated via inflammation inhibition. Mechanistic characterizations indicate that TIGAR directly binds to transforming growth factor β-activated kinase (TAK1) and promotes tumor necrosis factor receptor-associated factor 6-mediated ubiquitination and auto-phosphorylation of TAK1, in which residues 152-161 of TIGAR constitute crucial motif independent of its phosphatase activity. Interference with the binding of TIGAR to TAK1 by 5Z-7-oxozeaenol exhibits therapeutic effects in male murine model of sepsis. These findings demonstrate a non-canonical function of macrophage TIGAR in promoting inflammation, and confer a potential therapeutic target for sepsis by disruption of TIGAR-TAK1 interaction.
- Open Access
- 13 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-11
Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts
Osteoclasts (OCs), derived from monocyte/macrophage lineage, are key orchestrators in bone remodeling. Targeting osteoclast apoptosis is a promising approach to cut down excessive osteoclast numbers, and thus slow down the rate of bone mass loss that inevitably occurs during aging. However, the therapeutic target of apoptosis in osteoclasts has not been fully studied. Our previous work generated Mvpf/fLyz2-Cre mice, conditionally depleting major vault protein (MVP) in monocyte lineage, and identified MVP as a bone protector for its negative role in osteoclastogenesis in vivo and in vitro. Here, we observed a notable decline of MVP in osteoclasts with aging in mice, encouraging us to further investigate the regulatory role of osteoclast MVP. Then, Mvpf/fLyz2-Cre mice were exploited in two osteoporosis contexts, aging and abrupt loss of estrogen, and we revealed that conditional knockout of MVP inhibited osteoclast apoptosis in vivo and in vitro. Moreover, we reported the interaction between MVP and death receptor Fas, and MVP-Fas signaling cascade was identified to positively regulate the apoptosis of osteoclasts, thus preventing osteoporosis. Collectively, our comprehensive discovery of MVP’s regulatory role in osteoclasts provides new insight into osteoclast biology and therapeutic targets for osteoporosis.
- 13 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-11
Open AccessMajor vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts
Osteoclasts (OCs), derived from monocyte/macrophage lineage, are key orchestrators in bone remodeling. Targeting osteoclast apoptosis is a promising approach to cut down excessive osteoclast numbers, and thus slow down the rate of bone mass loss that inevitably occurs during aging. However, the therapeutic target of apoptosis in osteoclasts has not been fully studied. Our previous work generated Mvpf/fLyz2-Cre mice, conditionally depleting major vault protein (MVP) in monocyte lineage, and identified MVP as a bone protector for its negative role in osteoclastogenesis in vivo and in vitro. Here, we observed a notable decline of MVP in osteoclasts with aging in mice, encouraging us to further investigate the regulatory role of osteoclast MVP. Then, Mvpf/fLyz2-Cre mice were exploited in two osteoporosis contexts, aging and abrupt loss of estrogen, and we revealed that conditional knockout of MVP inhibited osteoclast apoptosis in vivo and in vitro. Moreover, we reported the interaction between MVP and death receptor Fas, and MVP-Fas signaling cascade was identified to positively regulate the apoptosis of osteoclasts, thus preventing osteoporosis. Collectively, our comprehensive discovery of MVP’s regulatory role in osteoclasts provides new insight into osteoclast biology and therapeutic targets for osteoporosis.
- Open Access
- 10 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Ferritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis
Hyperferritinemic syndrome, an overwhelming inflammatory condition, is characterized by high ferritin levels, systemic inflammation and multi-organ dysfunction, but the pathogenic role of ferritin remains largely unknown. Here we show in an animal model that ferritin administration leads to systemic and hepatic inflammation characterized by excessive neutrophil leukocyte infiltration and neutrophil extracellular trap (NET) formation in the liver tissue. Ferritin-induced NET formation depends on the expression of peptidylarginine deiminase 4 and neutrophil elastase and on reactive oxygen species production. Mechanistically, ferritin exposure increases both overall and cell surface expression of Msr1 on neutrophil leukocytes, and also acts as ligand to Msr1 to trigger the NET formation pathway. Depletion of neutrophil leukocytes or ablation of Msr1 protect mice from tissue damage and the hyperinflammatory response, which further confirms the role of Msr1 as ferritin receptor. The relevance of the animal model is underscored by the observation that enhanced NET formation, increased Msr1 expression and signalling on neutrophil leukocytes are also characteristic to adult-onset Still’s disease (AOSD), a typical hyperferritinemic syndrome. Collectively, our findings demonstrate an essential role of ferritin in NET-mediated cytokine storm, and suggest that targeting NETs or Msr1 may benefit AOSD patients.
- 10 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessFerritin triggers neutrophil extracellular trap-mediated cytokine storm through Msr1 contributing to adult-onset Still’s disease pathogenesis
Hyperferritinemic syndrome, an overwhelming inflammatory condition, is characterized by high ferritin levels, systemic inflammation and multi-organ dysfunction, but the pathogenic role of ferritin remains largely unknown. Here we show in an animal model that ferritin administration leads to systemic and hepatic inflammation characterized by excessive neutrophil leukocyte infiltration and neutrophil extracellular trap (NET) formation in the liver tissue. Ferritin-induced NET formation depends on the expression of peptidylarginine deiminase 4 and neutrophil elastase and on reactive oxygen species production. Mechanistically, ferritin exposure increases both overall and cell surface expression of Msr1 on neutrophil leukocytes, and also acts as ligand to Msr1 to trigger the NET formation pathway. Depletion of neutrophil leukocytes or ablation of Msr1 protect mice from tissue damage and the hyperinflammatory response, which further confirms the role of Msr1 as ferritin receptor. The relevance of the animal model is underscored by the observation that enhanced NET formation, increased Msr1 expression and signalling on neutrophil leukocytes are also characteristic to adult-onset Still’s disease (AOSD), a typical hyperferritinemic syndrome. Collectively, our findings demonstrate an essential role of ferritin in NET-mediated cytokine storm, and suggest that targeting NETs or Msr1 may benefit AOSD patients.
- Top Cited PapersOpen Access
- 3 March 2022
- Published by Elsevier in Molecular Metabolism
- Vol. 59, 101462
Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway
- 3 March 2022
- Published by Elsevier in Molecular Metabolism
- Vol. 59, 101462
Top Cited PapersOpen AccessSerum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway
- Open Access
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (15) , 7247-7261
Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition
Rationale: Bone homeostasis is maintained by a balanced interplay of osteoblasts and osteoclasts. Osteoclasts are derived from monocyte/macrophage lineage. Major vault protein (MVP) is known to promote apoptosis and prevent metabolic diseases in macrophage. However, whether MVP is involved in osteoclastogenesis is unknown. Here, we identified an important function of MVP as a negative regulator of osteoclastogenesis and its therapeutic potential in preventing bone loss.
- 1 January 2021
- Published by Ivyspring International Publisher in Theranostics
- Vol. 11 (15) , 7247-7261
Open AccessMajor vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition
Rationale: Bone homeostasis is maintained by a balanced interplay of osteoblasts and osteoclasts. Osteoclasts are derived from monocyte/macrophage lineage. Major vault protein (MVP) is known to promote apoptosis and prevent metabolic diseases in macrophage. However, whether MVP is involved in osteoclastogenesis is unknown. Here, we identified an important function of MVP as a negative regulator of osteoclastogenesis and its therapeutic potential in preventing bone loss.